In New York Medical College (USA) a clinical study on the use of mesenchymal stem cells of placenta in the treatment of a number of serious blood diseases and genetic metabolism disorders launched. The study will include both men and women under the age of 55 years.

The purpose of Phase 1 of the project is to explore the safety of application of human placenta derived stem cells in conjunction with cord blood stem cells in the treatment of malignant and other diseases. Stem cell transplant will be preceded by chemotherapy.

 

The basic list of diseases in which innovation treatment will be used includes:

• Mucopolysaccharidosis I
• Mucopolysaccharidosis VI
• Adrenoleukodystrophy
• Niemann-Pick Disease
• Metachromatic Leukodystrophy
• Wolman Disease
• Krabbe’s Disease
• Gaucher’s Disease
• Fucosidosis
• Batten Disease
• Severe Aplastic Anemia
• Diamond-Blackfan Anemia
• Amegakaryocytic Thrombocytopenia
• Myelodysplastic Syndrome
• Acute Myelogenous Leukemia
• Acute Lymphocytic Leukemia

Many doctors of antiquity considered placenta as a valuable biological material, extracts of which have been widely used to stimulate wound healing. Modern manufacturing technologies allow to produce medicines of placental extracts for systemic use, which greatly increased the possibility of their application in various fields of medicine and cosmetology. However, in addition to the presence of important biologically active substances (growth factors , etc.) in placental tissue, placenta is a rich source of stem cells. In Ukraine, the Institute of Cell Therapy uses authors techniques of placenta stem cells separation and production of unique medicines based on placenta extracts.

Source: www.clinicaltrials.gov